- Home
- Signaling Pathways
- PI3K/Akt/mTOR Signaling
- PI3K
- CAL-101 (Idelalisib, GS-1101)
CAL-101 (Idelalisib, GS-1101)
CAL-101 (Idelalisib, GS-1101), is a p110δ selective phosphatidylinositol-3-kinase inhibitor in a kinome-wide screen using purified enzymes and in cell-based PI3K isoform-specific assays. Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival. CAL-101 can block constitutive phosphatidylinositol-3-kinase signaling, resulting in reduced phosphorylation of Akt and other downstream effect factors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis. These effects have been observed across a broad range of immature and mature B-cell malignancies. In addition, CAL-101 abrogated protection from spontaneous apoptosis induced by B cell–activating factors CD40L, TNF-α, and fibronectin.
Reference
Brian J. Lannutti, Sarah A. Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc M. Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, and Neill A. Giese. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117(2): 591 – 594.
Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, ?Amy J. Johnson. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12): 2078 – 88.
- 1. Daniel Pinto-Benito, Carmen Paradela-Leal, et al. "IGF-1 regulates astrocytic phagocytosis and inflammation through the p110α isoform of PI3K in a sex-specific manner." Glia. 2022 Jun;70(6):1153-1169. PMID: 35175663
- 2. Graeme F. Murray, Daniel Guest, et al. "Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population." Analyst. 2021 Feb 21;146(4):1157-1162. PMID: 33426547
- 3. Julia C Gutjahr, Elisabeth Bayer, et al. "CD44 Engagement Enhances Acute Myeloid Leukemia Cell Adhesion To The Bone Marrow Microenvironment By Increasing VLA-4 Avidity." Haematologica. 2020 Jul 2;haematol.2019.231944. PMID: 32616529
- 4. Wu W, Zhou G, et al. "PI3Kδ as a Novel Therapeutic Target in Pathological Angiogenesis." Diabetes. 2020;db190713. PMID: 31915155
- 5. Xin T, Han H, et al. "Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes." Exp Eye Res. 2019 Nov 28:107884. PMID: 31786159
- 6. Han H, Chen N, et al. "Phosphoinositide-3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells." J Biol Chem. 2019 Aug 29. pii: jbc.RA119.010130. PMID: 31467081
- 7. Yaya Chu, Sanghoon Lee, et al. " Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model." OncoImmunology.11 Oct 2018.
- 8. Wensveen FM, Slinger E, et al. "Antigen-affinity controls pre-germinal centser B cell selection by promoting Mcl-1 induction through BAFF receptor signaling." Sci Rep. 2016 Oct 20;6:35673. PMID: 27762293
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 415.43 |
| Cas No. | 870281-82-6 |
| Formula | C22H18FN7O |
| Synonyms | CAL-101,CAL101,Idelalisib,GS-1101,GS1101 |
| Solubility | insoluble in H2O; ≥2.1 mg/mL in EtOH with gentle warming and ultrasonic; ≥80.2 mg/mL in DMSO |
| Chemical Name | 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one |
| SDF | Download SDF |
| Canonical SMILES | CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment: [1] | |
|
Cell lines |
CD19/CD5-positive CLL cells (> 90%) |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
< 5 μM: dose-dependently inhibits the pro-survival effect of anti-IgM= 5 μM, 24h: inhibits 2.6% activity of anti-IgM> 5 μM, 72h: maximally reduces CLL cell viability |
|
Applications |
CAL-101 abrogated the pro-survival effect of anti-IgM in a dose-dependent fashion at lower dose levels (< 5 μM). CAL-101 treatment at concentrations of > 5 μM was maximally effective over the 72-hour time course in reducing CLL cell viability. At the 5 μM concentration, CAL-101 significantly decreased the mean ( SEM) pro-survival effect of anti-IgM to 92.7% ( 2.6%) after 24 hours. |
| Animal experiment : [2] | |
|
Animal models |
NOD-SCID-γ-null (NSG) mice well-engrafted with de novo (n = 3) or relapsed (n = 1) childhood Ph-like ALL specimens with JAK2 mutations and/or CRLF2 alterations. |
|
Dosage form |
30 mg/kg/day, 3 days, oral gavage |
|
Applications |
CAL101 treatments demonstrated potent in vivo inhibition of relevant phosphoproteins, including phosphorylated (p) PI3K, mTOR, S6, and AktS473. Increased phosphorylation of other measured proteins was not observed, suggesting that proximal inhibition effectively abrogated aberrant PI3K pathway signal transduction with minimal compensatory signaling upregulation. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Hoellenriegel J, Meadows S A, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood, 2011, 118(13): 3603-3612. [2] Li Y, Ryan T, Vincent T, et al. In vivo efficacy of PI3K pathway signaling inhibition for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood, 2013, 122(21): 2672-2672. |
|
| Description | CAL-101 (Idelalisib, GS-1101) is a selective inhibitor of p110δ with IC50 of 2.5 nM. | |||||
| Targets | p110δ | |||||
| IC50 | 2.5 nM | |||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
